AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06796881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The conventional exercise program
Description: Patients will undergo a 12-session exercise program for 6 weeks, consisting of straight leg raising, bridging exercise, prone hip extension exercise, and abdominal curl exercise. The exercises will be done 3 sets, 10 repetitions each, with 1 minute rest between each set. The abdominal curl exercises involve supine or hook-lying positions with the lumbar spine neutral, with the patient performing a drawing in maneuver to stabilize the abdominal muscles. The progression involves lifting the shoulders, changing arm positions, and holding a weight or medicine ball. The patient's position is hook-lying, maintaining a neutral spinal position.
Study NCT06793449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
Study NCT06793449 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ASCT
Description: Autologous stem cell infusion
Study NCT06797336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT0253
Description: PT0253 injection.
Study NCT06793436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest wall blocks
Description: The effects of anterior chest wall blocks (PECS and SAP will be used in this study) performed for postoperative analgesia on pain scores (to be checked with VAS), opioid consumption, length of hospital stay, mobilization time, side effects and complications in the postoperative period will be examined.
Study NCT06793436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest wall blocks
Description: The effects of anterior chest wall blocks (PECS and SAP will be used in this study) performed for postoperative analgesia on pain scores (to be checked with VAS), opioid consumption, length of hospital stay, mobilization time, side effects and complications in the postoperative period will be examined.
Study NCT06795321 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal anesthesia
Description: Patients who preferred spinal anesthesia were included in this group.
Study NCT06795321 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Patients who preferred spinal anesthesia were included in this group
Study NCT06796621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Respectful Online Space (BROS)
Description: Session 1 (40 minutes to 50 minutes): Respectful online relationship (Psychoeducation) using face-to-face approach with 40 minutes to 50 minutes online serious game Session 2 (40 minutes to 50 minutes): Navigating the online world (Psychoeducation) using face-to-face approach with 20 to 30 minutes online music therapy Session 3 (40 minutes to 50 minutes): Behaviour specific cognitions and reflection using face-to-face approach
Study NCT06796621 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy diet education program
Description: Session 1 (40 - 50 minutes): Healthy Diet Pyramid (Psychoeducation) using face-to-face approach Session 2 (40 - 50 minutes): Mindful Eating and Healthy Weight Management (Psychoeducation) using face-to-face approach Session 3 (40 - 50 minutes): Healthy Eating Habits for Life (Psychoeducation)using face-to-face approach
Study NCT05930938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant
Description: Xevinapant is a multi-IAP antagonist that blocks the activity of several IAPs including X-linked IAP (XIAP), cellular inhibitor of apoptosis proteins (cIAP) 1, cIAP2 and ML-IAP
Study NCT05930938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Xevinapant without active substance
Study NCT05930938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cetuximab
Description: cetuximab
Study NCT05930938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab
Study NCT05930938 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: IMRT
Description: IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction)
Study NCT05930938 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction)
Study NCT06792890 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Use Nabla AI Scribe tool provided
Description: AI Scribe technologies capture physician-patient conversations to create a transcript, then summarize the transcript in the form of a clinical notes. These tools are integrated into the EHR and automatically adds the generated text to the provider note. All physicians must inform patients about the recording and obtain their verbal consent, and instances of patients declining to consent are tracked.~Nabla leverages its proprietary speech-to-text to transform the conversation into a written context, combined with HIPAA compliant Large Language Models (LLM) like Azure OpenAI's GPT-4. Nabla does not store any audio.
Study NCT06792890 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Use AI Scribe tool provided by Vendor B
Description: AI Scribe technologies capture physician-patient conversations to create a transcript, then summarize the transcript in the form of a clinical notes. These tools are integrated into the EHR and automatically adds the generated text to the provider note. All physicians must inform patients about the recording and obtain their verbal consent, and instances of patients declining to consent are tracked.
Study NCT06796179 — intervention group
Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones with sunscreen products
Description: The treated zones with sunscreen products were exposed to Visible Light to induce skin pigmentation (144 J/cm²), 15 to 30 minutes after application.
Study NCT06796179 — intervention group
Intervention type: OTHER
Intervention: Visible Light Exposure - Untreated zone
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study NCT06797284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: repetitive transcranial magnetic stimulation, transcranial direct current stimulation, daytime timed bright light exposure (10,000 lux of intense white light)
Study NCT06792864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsteoprintCR
Description: Hybrid technique of 3D printed bone matrix based on polycaprolactone with tricalcium beta phosphate
Study NCT06792864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMAR SET GMV Endurance Gentamicin
Description: Patient undergoing cranioplasty with conventional technique using polymethylmethylmethacrylate-based surgical cement brand SMAR SET GMV Endurance Gentamicin.
Study NCT06794242 — intervention group
Intervention type: OTHER
Intervention: Body representation
Description: All the participants (controls and patients) in the study will follow the same experimental procedure, which consists of a single virtual reality session involving the estimation of leg length and an object.
Study NCT06795152 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational. Natural history study.
Study NCT06794515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cGMP-AAs alone (20 g of protein equivalent)
Description: cGMP-AAs alone (20 g of protein equivalent)
Study NCT06794515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple
Description: cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple
Study NCT06794515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil
Description: cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil
Study NCT06794359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Coronary Artery Bypass Grafting
Description: Minimally Invasive Coronary Artery Bypass Grafting will be accomplished by complete revascularization of all previous defined coronary targets through left anterior thoracotomy. On or off pump approach will be determined by the surgeon. For on pump cases, femoral canulation will be performed and aortic cross clamp will be used. Off Pump cases will be performed using Medtronic Octopus and Starfish NS. Intra operative Transit time flow measurement will be performed in all cases.
Study NCT06794359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass surgery
Description: Procedure: Conventional Coronary Artery Bypass Grafting will be accomplished by complete revascularization of all previous defined coronary targets through classical total sternotomy. On or off pump approach will be determined by the surgeon. Intra operative Transit time flow measurement will be performed in all cases.
Study NCT06797752 — intervention group
Intervention type: DEVICE
Intervention: OCTA Scan
Description: Optical Coherence Tomography Angiography before and after receiving the stellate ganglion nerve block.
Study NCT06794385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dinoprostone vaginal delivery system
Description: Pregnant women in this group will receive a vaginal delivery system containing 10 mg of dinoprostone for labor induction.
Study NCT06794385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose peroral misoprostol
Description: Participants will be induced with a low-dose oral formulation of misoprostol, administered per protocol at 25 mcg every 2 hours
Study NCT06793137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: This intervention involves administering the oral antibiotic metronidazole during the first seven days of radiotherapy for patients with locally advanced rectal adenocarcinoma who are undergoing total neoadjuvant treatment. Metronidazole is considered a safe medication, with a very low risk of adverse effects. It is commonly used to treat infections caused by anaerobic bacteria that are part of the intestinal microbiota. Additionally, it is well established that certain genera of anaerobic bacteria are linked to a poorer response to treatment.
Study NCT06793332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab Combined With TROP2 ADC
Description: Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;
Study NCT06796309 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Trak Telerehabilitation Platform
Description: The exercise protocol designed is carried out through TRAK, the digital rehabilitation tool.
Study NCT06796309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trak Telerehabilitation Platform
Description: The exercise protocol designed is carried out through TRAK, the digital rehabilitation tool.
Study NCT06796309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation Program
Description: Exercise protocol with the methodology of conventional clinical practice.
Study NCT06794593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesylate
Description: Oral Camostat Mesylate 200 mg x 3 daily for 4 days.
Study NCT06070298 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computer algorithms
Description: Collection of lightweight computer algorithms called ausculto™ that is designed to perform real-time heart sound analysis to detect heart murmur.
Study NCT06796478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Egoscue Excercises
Description: A. Elbow curls on the wall with abduction B. Elbow curls on the wall with adduction C. Overhead extension D. Open Up arm and chest E. Upper spinal twist. F. Spinal Twist G. Pelvic tilts H. Static back alone and static back with breathing I. Static wall. J. Air Bench Abdominal contraction in the static back position. K. Resisted Abduction L. Abductor press M. Supine groin progression
Study NCT06796478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization excercises
Description: A. Cat Pose \& Camel pose B. Pelvic tilt C. Hip flexor stretches D. Hamstring stretches E. Piriformis stretch F. Prone on elbow
Study NCT06793761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg, IV, 3 cycles
Study NCT06793761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75mg/m2, IV, 3 cycles
Study NCT06793761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 260mg, IV, 3 cycles
Study NCT06793683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bladder chemodenervation (Botox)
Description: BoNT-A (Botox) 200 U will be injected into the detrusor (bladder wall muscle).
Study NCT06793683 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bladder Sham (Saline) Injection Procedure
Description: 20mL placebo (saline only), will be injected into the detrusor (bladder wall muscle).
Study NCT06795061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Supported Exercise with Professional Guidance
Description: Participants will engage in small, peer-supported exercise groups (4-6 individuals) to coordinate weekly sessions (e.g., running, cycling, yoga). A professional coach provides knowledge-based guidance remotely, focusing on safe exercise techniques, injury prevention, basic nutrition, and motivation strategies, but does not conduct in-person training sessions. The aim is to improve adherence to physical activity and enhance mental well-being through peer accountability and evidence-informed coaching.
Study NCT06797661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: 11 minutes of Functional MRI alternating breathing Air-Room and gaz mix (5%CO2 21%O2 74%N2).~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution.
Study NCT06797661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: Some patients who did not benefit from a FDG-PET in their clinical evaluation or more than 1 month before the inclusion in the present study will be ask to also undergo a brain FDG-PET , the dose is set at 2 Mega becquerel per Kg.~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution.
Study NCT06797661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Structural MRI
Description: Patient will benefit Different anatomical sequence of acquisition listed here : T1 , T1 with contrast agent (gadovist) , T2 flair , T2 and DSC (Dynamic susceptibility contrast) , and Time Of Flight .~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution.
Study NCT06797011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High volume Plasma Exchange
Description: High volume Plasma Exchange with minimum 3 sessions on alternate days
Study NCT06797011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment includes stopping the offending drug,nutrition,injection NAC,Tablet UDCA,steroid in DILI AIH
Study NCT05343689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic compression
Description: Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
Study NCT05513365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg
Description: Goserelin injection (10.8 mg) once per 3 months until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
Study NCT05513365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg
Description: Bicalutamide tablets (50 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
Study NCT05463718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
Study NCT06797011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment includes stopping the offending drug,nutrition,injection NAC,Tablet UDCA,steroid in DILI AIH
Study NCT06794645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle
Study NCT06794645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Phase 2
Description: pemetrexed 900 mg/m2 IV on Day 1 of each 21-day treatment cycle and supportive medications (folic acid, vitamin B12, and dexamethasone).
Study NCT05513365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Description: Dutasteride capsules (0.5 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
Study NCT06282354 — intervention group
Intervention type: OTHER
Intervention: Type of post-operative appointment
Description: remote post-operative appointment for small or medium urooncology procedures
Study NCT06797128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Anchor
Description: Participant will receive one standard anchor
Study NCT06797128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two Mini Anchors
Description: Participant will receive two mini anchors
Study NCT06794528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RehbeCa mobile application
Description: The system consists of a mobile application (to be used by patients) and a web application (to be used by physiotherapists) that allows monitoring of the patient's performance without the need for attendance, thus facilitating telerehabilitation. The mobile application consists of a serious game that aims to induce the patient to perform neck exercises, adapting to their capacity and evolution at all times through artificial intelligence. The patient's interaction with the mobile application is based on the integration of a vision-based head-tracker to track the movements of the patient's head. The web application aims to provide professionals with a tool to monitor the evolution of their patients through the data captured by the mobile application.
Study NCT06794528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Set of therapeutic exercises to be carried out at home. They are taught face-to-face, and also printed on a leaflet that is delivered to the participant.
Study NCT06796387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation of SBAT
Description: For schools randomized to implementing SBAT, the program will include the components already available in comparison (usual care) schools (asthma symptom screening forms, access to telemedicine visits, and protocol for initiating DOT), as well as the following elements that will be facilitated with the support of an implementation team:~* Telemedicine asthma visits through school with primary care and/or specialist providers to prescribe needed initial medication as well as medication step-ups for DOT school-based DOT of preventive asthma medications~* Follow-up telemedicine asthma control assessments~* Centralized case management support~* Care coordination
Study NCT06796387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: During student health services orientation, the SBAT team will recommend school-based DOT for all children with persistent or poorly controlled asthma, and will provide a simple asthma screening survey to assess symptoms and a written protocol for initiating DOT. Telemedicine visits and DOT are available for all children in the school district, but the implementation team will not help to facilitate these components within the usual care schools.
Study NCT06797622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Description: Trastuzumab deruxtecan (T-DXd)
Study NCT06794333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal laser Ablation
Description: Treatments are performed with the combined EchoLaser EVO system (Elesta SpA - Calenzano, FI). The EchoLaser EVO consists of the Echolaser X4, a multi-source laser system with a wavelength of 1064 nm, and the Echolaser Smart Interface (ESI). The procedure are performed with the patient in the lithotomy position. Local anesthesia of the perineal region and periprostatic block with lidocaine is administered under ultrasound guidance. A catheter is placed during the irradiation to allow continuous irrigation of the urethra with saline solution, protecting the urethra from temperature rise. The Echolaser Smart Interface, defines: the number and positioning of fibers, the optimal dose, and the need for multiple pullbacks. 2 to 4 21G needles are inserted simultaneously (1 or 2 per lobe) in the peri-urethral area via transperineal ultrasound guidance. A 300-micron optical fiber will be placed in each needle. Each treatment delivers a maximum energy of 1800 J per fiber with a power of 3-5 W.